Contributions
Abstract: EP1239
Type: E-Poster Presentation
Session title: Stem cell transplantation - Clinical
Background
Although most of the patients with multiple myeloma (MM) or lymphoma eligible for autologous stem cell transplantation (ASCT) mobilize enough hematopoietic stem cells (HSCs), there are also patients in which mobilization is more difficult and several apheresis (aph) sessions are needed. For those poor mobilizers (PMs), data will be collected across Germany and adequate mobilization strategies will be established.
Aims
Aim of the OPTIMOB study is to assess the current approach of HSC mobilization and collection, and ASCT in PM patients in Germany to eventually improve mobilization and transplantation strategies, especially in PM patients.
Methods
The OPTIMOB study is an ongoing, prospective, non-interventional study including patients having MM or lymphoma who are eligible for ASCT. PMs are categorized as follows: (1) patient never achieved ≥ 20 CD34+ cells / µL before 1st aph (PM-A), (2) patient received plerixafor (PLX) at any time point of mobilization (PM-B), (3) the initially planned HSC yield had to be reduced (PM-C), or (4) patients have not received aph due to low CD34+ count in peripheral blood (PM-D).
Results
Until data cut-off in November 2020, 461 patients participated in the study, of whom 37.6% were classified as PMs. Most patients (67%) suffered from MM. Notable, the share of PMs was nearly the same in both entities, MM and lymphoma. In general, PMs were older, mostly male and had a poorer Karnofsky score. 68.2% of the PMs received plerixafor during mobilization, mainly in combination with chemotherapy and/or G-CSF (granulocyte-colony stimulating factor). PLX administration led to a notably increase of CD34+ cells in peripheral blood in PM patients (at least two-fold). Until data cut-off, 84.4% of the PMs were able to undergo aph. In general, patients with PLX supported mobilization had a higher mean total CD34+ collection result than PM patients without PLX administration (7.5 x106 cells/kg body weight (BW) [SD: ± 7.46] vs 5.2 x106 cells/kg BW [SD: ± 3.70]). Further, 72% of the PM patients treated with PLX (n=104) reached the total planned CD34+ collection target (median 6.0 x106 cells/kg BW) during aph whereas in patients without PLX administration, only 45.5% of the patients achieved this goal. ASCT was feasible in 66.5% of the PM patients until data cut-off.
Conclusion
The ongoing OPTIMOB study provides comprehensive data of the current situation of MM and lymphoma patients classified as PMs in Germany. Data support that additive administration of PLX to established mobilization strategies leads to a sufficient mobilization and collection of HSCs PM patients.
This non-interventional study is sponsored by Sanofi.
Keyword(s): Apheresis, Autologous hematopoietic stem cell transplantation, Mobilization, Multiple myeloma
Abstract: EP1239
Type: E-Poster Presentation
Session title: Stem cell transplantation - Clinical
Background
Although most of the patients with multiple myeloma (MM) or lymphoma eligible for autologous stem cell transplantation (ASCT) mobilize enough hematopoietic stem cells (HSCs), there are also patients in which mobilization is more difficult and several apheresis (aph) sessions are needed. For those poor mobilizers (PMs), data will be collected across Germany and adequate mobilization strategies will be established.
Aims
Aim of the OPTIMOB study is to assess the current approach of HSC mobilization and collection, and ASCT in PM patients in Germany to eventually improve mobilization and transplantation strategies, especially in PM patients.
Methods
The OPTIMOB study is an ongoing, prospective, non-interventional study including patients having MM or lymphoma who are eligible for ASCT. PMs are categorized as follows: (1) patient never achieved ≥ 20 CD34+ cells / µL before 1st aph (PM-A), (2) patient received plerixafor (PLX) at any time point of mobilization (PM-B), (3) the initially planned HSC yield had to be reduced (PM-C), or (4) patients have not received aph due to low CD34+ count in peripheral blood (PM-D).
Results
Until data cut-off in November 2020, 461 patients participated in the study, of whom 37.6% were classified as PMs. Most patients (67%) suffered from MM. Notable, the share of PMs was nearly the same in both entities, MM and lymphoma. In general, PMs were older, mostly male and had a poorer Karnofsky score. 68.2% of the PMs received plerixafor during mobilization, mainly in combination with chemotherapy and/or G-CSF (granulocyte-colony stimulating factor). PLX administration led to a notably increase of CD34+ cells in peripheral blood in PM patients (at least two-fold). Until data cut-off, 84.4% of the PMs were able to undergo aph. In general, patients with PLX supported mobilization had a higher mean total CD34+ collection result than PM patients without PLX administration (7.5 x106 cells/kg body weight (BW) [SD: ± 7.46] vs 5.2 x106 cells/kg BW [SD: ± 3.70]). Further, 72% of the PM patients treated with PLX (n=104) reached the total planned CD34+ collection target (median 6.0 x106 cells/kg BW) during aph whereas in patients without PLX administration, only 45.5% of the patients achieved this goal. ASCT was feasible in 66.5% of the PM patients until data cut-off.
Conclusion
The ongoing OPTIMOB study provides comprehensive data of the current situation of MM and lymphoma patients classified as PMs in Germany. Data support that additive administration of PLX to established mobilization strategies leads to a sufficient mobilization and collection of HSCs PM patients.
This non-interventional study is sponsored by Sanofi.
Keyword(s): Apheresis, Autologous hematopoietic stem cell transplantation, Mobilization, Multiple myeloma